Supportive treatments

Addition of doxycycline to ciprofloxacin for infection prophylaxis during autologous stem cell transplants for multiple myeloma. Sivik JM et al. Support Care Cancer. 2018 Mar 21. doi: 10.1007/s00520-018-4165-6. [Epub ahead of print]. Evaluation of the relevance of surgery in patients with multiple myeloma harboring symptomatic spinal involvement: a retrospective case series. Quidet M et al. World Neurosurg. 2018 Mar 9. pii: S1878-8750(18)30458-3. doi: 10.1016/j.wneu.2018.02.184.…

Journal, Library, Myeloma Prognosis & Outcomes

Related conditions

Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. Katodritou E et al. Blood Cancer J. 2018 Mar 9;8(3):31. doi: 10.1038/s41408-018-0059-6. Primary plasma cell leukemia in the era of novel agents for myeloma – a multicenter retrospective analysis of outcome. Ganzel C et…

Journal, Library

General

The impact of the introduction of bortezomib on dialysis independence in multiple myeloma patients with renal impairment: a nationwide Dutch population-based study. Oortgiesen BE et al. Haematologica. 2018 Mar 15. pii: haematol.2017.184754. doi: 10.3324/haematol.2017.184754. [Epub ahead of print]. Multiple Myeloma Presenting as a Superscan on 68Ga-Pentixafor PET/CT. Pan Q et al. Clin Nucl Med. 2018 Mar 13. doi: 10.1097/RLU.0000000000002067. [Epub ahead of…

Journal, Library

Diagnostic techniques and prognostic indicators

Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts. Marinac CR et al. Br J Cancer. 2018 Mar 12. doi: 10.1038/s41416-018-0010-4. [Epub ahead of print]. Multidrug resistance 1 (MDR1/ABCB1) gene polymorphism (rs1045642 C > T) and susceptibility to multiple myeloma: a systematic review and meta-analysis. Razi B et al. Hematology. 2018 Mar 1:1-7. doi: 10.1080/10245332.2018.1443897.…

Diagnosing and Monitoring Myeloma, Journal, Library

Current treatments

Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC. Augeul-Meunier K et al. Bone Marrow Transplant. 2018 Mar 9. doi: 10.1038/s41409-018-0122-8. [Epub ahead of print]. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation…

Journal, Library

Complications of myeloma and its treatments

Calcified Alveolar Septal Pulmonary Amyloidosis as an Initial Manifestation of Multiple Myeloma. Kevorkof GV et al. Arch Bronconeumol. 2018 Mar 5. pii: S0300-2896(18)30020-6. doi: 10.1016/j.arbres.2018.01.005. [Epub ahead of print]. Severe pembrolizumab-associated neutropenia after CD34+ selected allogeneic hematopoietic-cell transplantation for multiple myeloma. Bryant AR et al. Bone Marrow Transplant. 2018 Mar 7. doi: 10.1038/s41409-018-0142-4. [Epub ahead of print]. Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management,…

Journal, Library, Management of complications & side effects

Biology and genetics

Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw. Musolino C et al. Ann Hematol. 2018 Mar 15. doi: 10.1007/s00277-018-3296-7. [Epub ahead of print]. A novel nano-immunoassay method for quantification of proteins from CD138 purified myeloma cells: biological and clinical utility. Misiewicz-Krzeminska I et al. Haematologica. 2018 Mar 15. pii: haematol.2017.181628. doi: 10.3324/haematol.2017.181628. [Epub ahead…

Journal, Library, Management of Myeloma

Ixazomib combination demonstrates efficacy in relapsed and refractory myeloma patients

Results from a Phase II study, recently published in Leukaemia, show that the oral combination of ixazomib (Ninlaro®), pomalidomide (Imnovid®) and dexamethasone is effective in relapsed and refractory myeloma patients. All patients in this study were refractory to lenalidomide (Revlimid®). 48% of patients who received the recommended dose of ixazomib (4mg) achieved a partial response or…

News

Pomalidomide combination shows efficacy in relapsed and refractory myeloma patients with renal impairment

Published in the Journal of Clinical Oncology, results from the Phase II trial, MM-013 show that pomalidomide (Imnovid®) in combination with low-dose dexamethasone is effective in relapsed and refractory patients with renal impairment. There were 3 cohorts in this trial; patients with moderate renal impairment (A), severe renal impairment (B) and severe impairment requiring haemodialysis…

News